[go: up one dir, main page]

MA37316A1 - Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase - Google Patents

Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase

Info

Publication number
MA37316A1
MA37316A1 MA37316A MA37316A MA37316A1 MA 37316 A1 MA37316 A1 MA 37316A1 MA 37316 A MA37316 A MA 37316A MA 37316 A MA37316 A MA 37316A MA 37316 A1 MA37316 A1 MA 37316A1
Authority
MA
Morocco
Prior art keywords
pyrido
pyrimidine
inhibitors
amino
substituted
Prior art date
Application number
MA37316A
Other languages
English (en)
Other versions
MA37316B1 (fr
Inventor
Matthew Carl Allgeier
Daniel L Flynn
Michael D Kaufman
Phenil J Patel
Craig D Wolfangel
Original Assignee
Lilly Co Eli
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37316(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Deciphera Pharmaceuticals Llc filed Critical Lilly Co Eli
Publication of MA37316A1 publication Critical patent/MA37316A1/fr
Publication of MA37316B1 publication Critical patent/MA37316B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne le composé l-(3,3-dimethylbutyl) -3-(2-fluoro-4-methyl-5- (7-methyl-2-(methylamino)pyrido[2,3- d]pyrimidin-6-yl)phenyl)urée ou un sel de celui-ci pharmaceutiquement acceptable, qui inhibe raf et peut donc être utilisé pour traiter le cancer.
MA37316A 2012-03-07 2013-03-05 Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase MA37316B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07
PCT/US2013/029084 WO2013134243A1 (fr) 2012-03-07 2013-03-05 Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase

Publications (2)

Publication Number Publication Date
MA37316A1 true MA37316A1 (fr) 2016-06-30
MA37316B1 MA37316B1 (fr) 2017-03-31

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37316A MA37316B1 (fr) 2012-03-07 2013-03-05 Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase

Country Status (39)

Country Link
US (2) US9334267B2 (fr)
EP (1) EP2850082B1 (fr)
JP (1) JP2015509536A (fr)
KR (1) KR20140129087A (fr)
CN (1) CN104302646B (fr)
AP (1) AP2014007899A0 (fr)
AR (1) AR090151A1 (fr)
AU (1) AU2013230146B2 (fr)
BR (1) BR112014018528A8 (fr)
CA (1) CA2863673A1 (fr)
CL (1) CL2014002220A1 (fr)
CO (1) CO7010837A2 (fr)
CR (1) CR20140378A (fr)
CY (1) CY1117846T1 (fr)
DK (1) DK2850082T3 (fr)
DO (1) DOP2014000200A (fr)
EA (1) EA024824B1 (fr)
EC (1) ECSP14017584A (fr)
ES (1) ES2584387T3 (fr)
HK (1) HK1202541A1 (fr)
HR (1) HRP20160654T1 (fr)
HU (1) HUE028095T2 (fr)
IL (1) IL234052A (fr)
IN (1) IN2014MN01575A (fr)
LT (1) LT2850082T (fr)
MA (1) MA37316B1 (fr)
ME (1) ME02423B (fr)
MX (1) MX2014010701A (fr)
NZ (1) NZ627454A (fr)
PE (1) PE20142338A1 (fr)
PH (1) PH12014501986B1 (fr)
PT (1) PT2850082T (fr)
RS (1) RS54840B1 (fr)
SG (1) SG11201404969YA (fr)
SI (1) SI2850082T1 (fr)
TN (1) TN2014000375A1 (fr)
TW (1) TW201348233A (fr)
UA (1) UA112340C2 (fr)
WO (2) WO2013134252A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
BR112018075371A2 (pt) * 2016-06-10 2019-03-19 Novartis Ag usos terapêuticos de um inibidor de c-raf
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
EP3615083A4 (fr) * 2017-04-28 2021-05-19 Zamboni Chem Solutions Inc. Composés conjugués de dégradation de raf
FI3728254T3 (fi) 2017-12-21 2023-05-05 Boehringer Ingelheim Int Bentsyyliaminosubstituoidut pyridopyrimidinonit ja johdannaiset SOS1-estäjinä
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
MX2020008015A (es) 2018-01-31 2020-10-16 Deciphera Pharmaceuticals Llc Terapia de combinación para el tratamiento de la mastocitosis.
EP3849536A4 (fr) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Polythérapies
CN113453684B (zh) 2018-12-28 2024-05-14 德西费拉制药有限责任公司 用于治疗癌症的csf1r抑制剂
SI3921030T1 (sl) 2019-02-06 2024-03-29 Eli Lilly And Company Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)sečnine kot ojačevalci kcnq
EP3927433A1 (fr) 2019-02-18 2021-12-29 Genentech, Inc. Composés de pyrido-pyrimidinyle et procédés d'utilisation
CA3138300A1 (fr) 2019-05-03 2020-11-12 Kinnate Biopharma Inc. Inhibiteurs de kinases raf
ES2962852T3 (es) 2019-05-10 2024-03-21 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de los mismos
AU2020275392B2 (en) 2019-05-10 2023-09-14 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3983081A1 (fr) 2019-06-17 2022-04-20 Deciphera Pharmaceuticals, LLC Inhibiteurs de l'autophagie à base d'amide d'aminopyrimidine et leurs procédés d'utilisation
WO2021030405A1 (fr) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
CN116234806A (zh) 2020-06-02 2023-06-06 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
WO2022060996A1 (fr) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibiteurs de raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
CA3198943A1 (fr) 2020-11-18 2022-05-27 Daniel L. Flynn Inhibiteurs des kinases gcn2 et perk et leurs methodes d'utilisation
TW202241885A (zh) 2020-12-22 2022-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｓｏｓ１抑制劑及其用途
EP4326256A1 (fr) 2021-04-23 2024-02-28 Kinnate Biopharma Inc. Traitement du cancer avec un inhibiteur de raf
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
CN118574836A (zh) 2021-12-01 2024-08-30 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-胺基-3-氰基噻吩及衍生物
WO2023099624A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
JP2024543976A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
WO2023099608A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
CN118591540A (zh) 2021-12-01 2024-09-03 勃林格殷格翰国际有限公司 包含环状2-氨基-3-氰基噻吩的kras降解化合物
TW202340209A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
JP2024546107A (ja) 2021-12-09 2024-12-17 デシフェラ・ファーマシューティカルズ，エルエルシー Ｒａｆキナーゼ阻害剤及びその使用方法
CN118434735A (zh) 2021-12-23 2024-08-02 勃林格殷格翰国际有限公司 8-氮杂喹唑啉作为脑渗透sos1抑制剂
WO2023173017A1 (fr) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Inhibiteurs de kras pour le traitement d'une maladie
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US20240174642A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
US20240166629A1 (en) 2022-10-26 2024-05-23 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
AR130849A1 (es) 2022-10-26 2025-01-22 Boehringer Ingelheim Int Compuestos heterocíclicos con capacidad para activar el receptor sting
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2024246099A1 (fr) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés spirocycliques et dérivés pour le traitement du cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447405A4 (fr) * 2001-10-17 2005-01-12 Kirin Brewery Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
US20080207617A1 (en) * 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8901137B2 (en) * 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Also Published As

Publication number Publication date
RS54840B1 (sr) 2016-10-31
EP2850082B1 (fr) 2016-05-18
ECSP14017584A (es) 2016-01-29
IN2014MN01575A (fr) 2015-05-08
US9334267B2 (en) 2016-05-10
CN104302646A (zh) 2015-01-21
PE20142338A1 (es) 2015-01-10
CY1117846T1 (el) 2017-05-17
MA37316B1 (fr) 2017-03-31
US20150119392A1 (en) 2015-04-30
CO7010837A2 (es) 2014-07-31
CL2014002220A1 (es) 2015-06-05
SI2850082T1 (sl) 2016-07-29
DOP2014000200A (es) 2014-10-15
SG11201404969YA (en) 2014-10-30
EA201491456A1 (ru) 2014-12-30
PH12014501986A1 (en) 2014-11-24
UA112340C2 (uk) 2016-08-25
ES2584387T3 (es) 2016-09-27
JP2015509536A (ja) 2015-03-30
BR112014018528A2 (fr) 2017-06-20
HK1202541A1 (en) 2015-10-02
PT2850082T (pt) 2016-07-15
US20130252977A1 (en) 2013-09-26
BR112014018528A8 (pt) 2017-07-11
EP2850082A1 (fr) 2015-03-25
HUE028095T2 (en) 2016-11-28
PH12014501986B1 (en) 2014-11-24
ME02423B (fr) 2016-09-20
AU2013230146A1 (en) 2014-08-14
MX2014010701A (es) 2015-03-10
NZ627454A (en) 2016-09-30
AU2013230146B2 (en) 2015-09-10
AP2014007899A0 (en) 2014-08-31
KR20140129087A (ko) 2014-11-06
LT2850082T (lt) 2016-09-12
HRP20160654T1 (hr) 2016-07-01
US8741911B2 (en) 2014-06-03
TW201348233A (zh) 2013-12-01
WO2013134252A1 (fr) 2013-09-12
DK2850082T3 (en) 2016-08-15
IL234052A (en) 2016-05-31
AR090151A1 (es) 2014-10-22
WO2013134243A1 (fr) 2013-09-12
EA024824B1 (ru) 2016-10-31
CA2863673A1 (fr) 2013-09-12
TN2014000375A1 (en) 2015-12-21
CR20140378A (es) 2014-11-27
CN104302646B (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
MA37316B1 (fr) Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
EP3492462A4 (fr) Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MX2018015422A (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridini lo.
MX2016007371A (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
MX2014005766A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met.
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
JOP20190143A1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
PH12017501123A1 (en) Solid state forms of fused heteroaromatic pyrrolidinones
NZ722624A (en) Fused pyrimidines as inhibitors of p97 complex
EA202091475A1 (ru) ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX366839B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
EP3679042A4 (fr) Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta
MX366840B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
EA201791743A1 (ru) Производные имидазо[2,1-в]тиазола и 5,6-дигидроимидазо[2,1-в]тиазола, применяемые в качестве s100-ингибиторов
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors